Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rosann Giesting

Clinical Nurse Specialist, Adult Health Fairfield, OH Nurse Practitioner

NPI 1508882598 CMS profile 10866470

3000 Mack Rd Ste 100, Fairfield, OH 45014

Open in the dashboard

General payments

$3,168

172 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rosann Giesting of Fairfield, OH is reported in the CMS Open Payments database as having received $3,168 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17 1
2024 General $19 1
2023 General $225 6
2022 General $1,712 109
2021 General $1,195 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rosann Giesting
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Rosann Giesting were reported at $17. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Rosann Giesting Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,195 $133 $48–$445 $132
2022 $1,712 $163 $57–$526 $149
2023 $225 $173 $64–$597 $160
2024 $19 $171 $54–$575 $164
2025 $17 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $732 30 payments
  2. Abbott Laboratories $333 5 payments
  3. Novartis Pharmaceuticals Corporation $313 25 payments
  4. Amgen Inc. $268 22 payments
  5. Pfizer Inc. $251 12 payments
  6. AstraZeneca Pharmaceuticals LP $220 7 payments
  7. Actelion Pharmaceuticals US, Inc. $214 17 payments
  8. Janssen Pharmaceuticals, Inc $188 13 payments
  9. Merck Sharp & Dohme Corporation $109 7 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $107 7 payments
  11. Other $432 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,154 171 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. JARDIANCE $732 30 payments
  2. Repatha $268 22 payments
  3. ENTRESTO $212 18 payments
  4. OPSUMIT $202 15 payments
  5. XARELTO $188 13 payments
  6. VYNDAQEL $181 7 payments
  7. CardioMEMS HF System $161 1 payment
  8. LEQVIO $137 11 payments
  9. FARXIGA $133 2 payments
  10. AMPLATZER $127 1 payment
  11. Other $1,108 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

3,166

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$706,011

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

23.9%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 415 $400,021
Jardiance Empagliflozin Brand 182 $214,368
Farxiga Dapagliflozin Propanediol Brand 36 $43,701
Eliquis Apixaban Brand 11 $17,663
Midodrine Hcl Generic 79 $6,162
Spironolactone Generic 525 $2,835
Metoprolol Succinate Generic 263 $2,731
Valsartan Generic 165 $2,729
Digoxin Generic 134 $2,507
Carvedilol Generic 268 $2,461

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$79,817

Medicare's payments for the services billed

Medicare patients

405

Average age 77

Services billed

1,647

169 women, 236 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 74%
Atrial fibrillation 61%
Chronic kidney disease 56%
Diabetes 55%
Arthritis 53%
COPD 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record